CGEN Compugen
- 2.0100
- -0.0800-3.83%
- 2.0600
- +0.0500+2.49%
Compugen News
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Investors Don't See Light At End Of Compugen Ltd.'s (NASDAQ:CGEN) Tunnel And Push Stock Down 26%
Compugen Ltd. (NASDAQ:CGEN) shareholders that were waiting for something to happen have been dealt a blow with a 26% share price drop in the last month.
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer With Liver Metastases at ASCO 2024
HOLON, Israel, April 25, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced
Compugen Reports Publication Of Paper In Cancer Immunology Research Demonstrating Therapeutic Potential Of COM503
Compugen Reports Publication Of Paper In Cancer Immunology Research Demonstrating Therapeutic Potential Of COM503
Compugen to Participate in Two Upcoming Investor Conferences
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Truist Financial Reaffirms Their Buy Rating on Compugen (CGEN)
Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) Is a Great Choice
Compugen Selected for Two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Is Maintained at Buy by Truist Securities
Compugen Is Maintained at Buy by Truist Securities
Truist Securities Maintains Buy on Compugen, Raises Price Target to $5
Truist Securities analyst Asthika Goonewardene maintains Compugen (NASDAQ:CGEN) with a Buy and raises the price target from $4 to $5.
Compugen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/08/2024 89.39% Truist Securities $4 → $5 Maintains Buy 12/19/2023 51.52% Stifel $3 → $4 Maintains Buy 0
Analysts Offer Insights on Healthcare Companies: Cigna (CI), Compugen (CGEN) and OrthoPediatrics (KIDS)
Compugen Ltd. (NASDAQ:CGEN) Held Back By Insufficient Growth Even After Shares Climb 26%
Compugen Ltd. (NASDAQ:CGEN) shares have continued their recent momentum with a 26% gain in the last month alone. The annual gain comes to 258% following the latest surge, making investors sit up an
Compugen Ltd. (NASDAQ:CGEN) Q4 2023 Earnings Call Transcript
Buy Rating Justified by Compugen's Positive Clinical Outlook and Financial Stability
Earnings Call: Compugen Reports Solid 2023 Results, Plans for Future Growth
Compugen to Present Data Reflecting Its Diversified Immuno-Oncology Pipeline at AACR 2024
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Earnings Call Summary | Compugen(CGEN.US) Q4 2023 Earnings Conference
The following is a summary of the Compugen Ltd. (CGEN) Q4 2023 Earnings Call Transcript:Financial Performance:Compugen had approximately $51.1 million in cash, cash equivalents, restricted cash, and c
Regenxbio, Quoin Pharmaceuticals, Renalytix Among Healthcare Movers
Interleukin-18 (IL-18) Inhibitor Market Research Report 2024: Insight Into Pipeline Landscape Featuring AB2 Bio, Simcha Therapeutics, GSK, Novartis, Olatec Therapeutics, Compugen, Lassen Therapeutics - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.In the rapidly advancing field of medical research,
Analysis
Price Target
No Data
